Ronapreve Drug Under Review for COVID-19

Ronapreve Drug Approved for Review for Covid-19 Treatment BRUSSELS (AA) - The European Medicines Agency (EMA), the pharmaceutical regulator of the European Union (EU), has accepted for review a marketing authorization application for "Ronapreve," a drug developed for the treatment of novel coronavirus (Covid-19). According to a written statement from the EMA, a marketing authorization application has been submitted for "Ronapreve," a monoclonal antibody therapy jointly developed by Swiss pharmaceutical company Roche and US-based Regeneron, for market approval in Europe. The statement noted that the drug will be used in the treatment of individuals over 12 years of age who do not require supplemental oxygen therapy and are at high risk of progression to severe disease, and can also be used for disease prevention in the same age group. The statement also noted that since the EMA's committee on medicinal products had previously reviewed data on the drug containing the active substances "casirivimab and imdevimab," it could respond to the marketing authorization application within two months.